82392-83-4

Usage

Derivative of acetamidine

A stable organic base used in pharmaceuticals and organic synthesis

Use as a reagent

In the synthesis of various organic compounds

Employed as an intermediate

In the production of pharmaceuticals and agrochemicals

Low solubility in water

Not easily dissolved in water

Ability to form stable complexes with metal ions

Useful in catalytic and coordination chemistry

Toxic if ingested or inhaled

Requires appropriate safety precautions during handling

Potential applications

In the medical and agricultural industries

Upstream product

• 10160-87-9 Propiolaldehyde diethyl acetal 
• 6136-93-2 2,2-diethoxyacetonitrile 

Relevant academic research and scientific papers

Development of an efficient, scalable route for the preparation of a novel insulin-like growth factor-1 receptor modulator

A chromatography-free and efficient synthesis of insulin-like growth factor-1 receptor (IGF-1R) modulator is reported. Herein we describe an improved synthesis for the target compound, which features facile introduction of a novel pyrrolidinyl-pyrimidyl isoxazole 8, via in situ sulfone displacement by fluorine. The overall process consists of six chemical steps and five isolations, with introduction of the expensive triheterocyclic unit 8 towards the end of the synthesis.

Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: Reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect

A series of novel imidazoline derivatives was synthesized and evaluated as neuropeptide Y (NPY) Y5 receptor antagonists. Optimization of previously reported imidazoline leads, 1a and 1b, was attempted by introduction of substituents at the 5-position on the imidazoline ring and modification of the bis(4-fluorphenyl) moiety. A number of potent derivatives without human ether-a-go-go related gene potassium channel (hERG) activity were identified. Selected compounds, including 2a, were shown to have excellent brain and CSF permeability. Compound 2a displayed a suitable pharmacokinetic profile for chronic in vivo studies and potently inhibited D-Trp34NPY-induced acute food intake in rats. Oral administration of 2a resulted in a potent reduction of body weight in a diet-induced obese mouse model.